Antihemophilic factor human is a Factor VIII replacement therapy used to treat hemophilia A. Antihemophilic factor human, also known as Coagulation Factor VIII or Anti-Hemophilic Factor (AHF), is a non-recombinant, lyophilized concentrate of coagulation factor VIII, an endogenous protein and essential component of the coagulation cascade.
- Mechanism
- Curator reviewed · 2 references
The human antihemophilic factor replaces the coagulation factor VIII. It acts as a co-factor for factor IX to activate factor X in the intrinsic pathway of blood coagulation.
- Primary indication
- The human antihemophilic factor is indicated for the cases of hemophilia A, also known as classical hemophilia for the prevention and control of hemorrhagic episodes.Curator reviewed · 6 structured indications
- Formula / weight
- 480000.0 Da (active (coagulant activity))
- First approval
- Canada, 2002 · United States, 1988 · European Union, 2021
- Also known as
- Antihemophilic factor VIII human · Antihemophilic factor, human · Antihemophilic factor, human (monoclonal) · Antihemophilic factor,human · F8 protein, human
- Brand names
Resolves to
What you can answer from here — as of October 30, 2025
Which drugs share a target with Antihemophilic factor human, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account